From: healerstouch1 <healerstouch1@a...>
Date: Tue Apr 4, 2000 9:47pm
Subject: Ellagic Acid Breast Cancer Testimonial



This is one of two breast cancer testimonials that I have. I will be happy
to fax the other one since it is not in my database. Please note that I
am in no way suggesting that someone quit seeing their doctor and
just take ellagic acid. I am not a doctor, I am simply a healer and
researcher who is trying to get this message out there. Please
see the current research on ellagic acid on this site by the Washington
D.C. Red Raspberry Commission.
<A HREF="http://www.red-raspberry.com/">Washington D.C. Red Raspberry
Commission</A>

Good health,

Steve
P.S. Feel free to e-mail me for a copy of a healing vegetarian diet
that is based on the acid and alkaline principle. Based on
actual studies under a darkfield microscope and research by
Japanese scientist Aihara who has a must book for all cancer
patients titled: "Acid & Alkaline."



Arom Lyyski's breast cancer Ellagic Acid testimonial

22 October 1999 - Consulted with a General Surgeon and it was determined
that the lump in her breast needed to be removed and a biopsy taken.

27 October 1999 - Breast biopsy performed and lump removed.

01 November 1999 - Result of biopsy was positive for cancer.

12 November - 1999 At the recommendation of the general surgeon we
went ahead with a Lumpectomy and a sampling of a lymph gland.

15 November 1999 - Started taking Ellagic Acid Red 21 (3 morning,
2 afternoon, 3 bedtime), Started taking Livosin to help assist the liver,
(6 per day; 3 morning, 3 evening).

18 November - The results of the Lumpectomy and Lymph Glands were
positive on the surrounding tissue of the breast and 7 of 18 positive lymph
glands. The diagnosis is---advanced Stage 3 cancer.

Recommendation: Full breast mastectomy, followed with radiation and
chemotherapy as soon as possible.

Decision: Get a second opinion from an Oncologist.

23 November 1999 - Went for a lung scan just to be sure.

26 November - 1999 - Went in for a bone scan just as a precaution.
Consulted with an Oncologist and received the same reccomendation.
Asked him if he would do the blood work (CA 27:29, Breast Cancer)
and he would.

Had blood taken after leaving the Oncologist office.

30 November 1999 - Lung scan and Bone scan both are negative.
Blood test results are received. CA 27.29 preferred range is less
than <37.7, her results were 14.9!

CANCER FREE!

*Ellagic Acid is made from the Meeker red raspberry.

******************************************************************************
******
David H. Barch, MD

Associate Professor of Medicine

My research explores chemical carcinogenesis with a special interest in the
role of dietary factors in modulating carcinogenesis. We have examined the
mechanisms through which dietary zinc deficiency increases carcinogenesis and
the mechanisms through which dietary ellagic acid reduces carcinogenesis.
These studies have demonstrated that dietary zinc deficiency increases the
cytochrome P-450-dependent activation of carcinogens while ellagic acid
inhibits P-450-dependent carcinogen activation. We have also demonstrated
that dietary ellagic acid induces a number of Phase II cellular
detoxification enzymes that detoxify activated carcinogens. In addition, we
have demonstrated that ellagic acid also binds to DNA and prevents the
attachment of DNA adducts to the O6 position of guanine. Our current studies
continue to examine the mechanisms involved in the transcription regulation
of the Phase II detoxification enzymes by anticarcinogens, as well as the
changes in the regulation of these detoxification enzymes during normal
development.

Barch, D.H., Rundhaugen, L.M., Thomas, P.E., Pillay, N.S., and Kardos, P.
(1994). Dietary ellagic acid inhibits the enzymatic activity of CYP1A1
without altering hepatic concentrations of CYP1A1 or CYP1A1 mRNA. Biochem
Biophys Res Commun 201: 1477-1482.

Barch, D.H., and Rundhaugen, L.M. (1994). Ellagic acid induces
NAD(P)H:quinone reductase through activation of the antioxidant regulatory
element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis 15:
2065-2068.

Barch, D.H., Rundhaugen, L.M., and Pillay, N.S. In press. (1995). Ellagic
acid induces transcription of the rat glutathione S-transferase Ya gene.
Carcinogenesis.

To all Oncologist's:

The Hollings Cancer instititute at the University of South Carolina
is doing a double blind study on a large group of 500 cervical cancer
patients that has everyone excited. They are excited because
their past nine years of study have shown that a natural product 
called ellagic acid is causing G-arrest within 48 hours (inhibiting and
stopping mitosis-cancer cell division), and apoptosis (normal cell
death) within 72 hours, for breast, pancreas, esophageal, skin, colon
and prostate cancer cells. Clinical tests also show that ellagic
acid prevents the destruction of the p53 gene by cancer cells.
Additional studies suggest that one of the mechanisms by which
ellagic acid inhibits mutagenesis and carcinogenesis is by forming
adducts with DNA, thus masking binding sites to be occupied by the
mutagen or carcinogen.

Ellagic acid can be found in different foods, but the clinic has identified
the red raspberry as having the highest content of the acid. Moreover, the
doctors at Holling's have created a patent pending process of extracting
potent levels of the acid from the seeds of the raspberrys that are getting 
dramatic results. Other USA sources substantiate the Hollings
Cancer Institute include:

Department of Surgical Oncology, College of Medicine, University of
Illinois at Chicago, Illinois; Division of Environmental Health Sciences, 
The Ohio State University School of Public Health, Colombus, Ohio; 
Departmant of Medicine, Lakeside Veterans Affairs Medical Center,
Northwestern University School of Medicine, Stanford, CA; Department
of Preventative Medicine, Ohio State University, Colombus, Ohio.

Here is a description of the study which came from a website of the
Washington Raspberry Commission. You can see the Hollings research
articles there.
http://www.red-raspberry.com/

Here are some notes from the site. Reprinted by permission from WRC

"The proposed study, under the direction of Daniel Nixon, M.D., President of 
the American Health Foundation and Drs. Dave Gangemi and Blair Holliday of 
the Hollings Cancer Center/Medical University of South Carolina, will 
evaluate women with atypical squamous cells of undetermined significance 
(ASCUS) in which there is neither treatment nor clinical evaluation 
available. ASCUS represents as much as 10% of all Papanicolaou smears in the 
US and represents approximately 5 million females. In this population, these 
women who are infected with human papillomaviruses (HPV) types 16 and/or 18 
are at the greatest risk of developing cervical cancer at some stage in their 
lives. In addition, women who are diagnosed with the immature metaplastic 
form of ASCUS usually have lesions which are higher in the endocervical 
canal, are more metabolically active, have flatter surface areas, and are 
more likely to invade the underlying connective tissue as well as the 
endocervical glandular epithelium. This population represents approximately 
one million women in the United States alone. The condition is very 
pronounced in countries outside the United States. In India this is one of 
the two major cancers affecting women."

Research sources:

Cancer Lett 1999 Mar 1 1;136(2):215-21
Expression and its posssible role in G1 arrest and apoptosisi in ellagic
acid treated cancer cells.
Narayanan BA, Geoffroy O, Wilmington MC, Re GG, Nixon DWCANCER P
Prevention program, Hollings Cancer Center, Medical University of South
Carolina, Charleston 29425, USA.

"Ellagia acid is a phenolic compound present in fruits and nuts including 
raspberries, strawberries and walnuts. It is known to inhibit certain
carcinogen-induced cancers and may have other chemopreventive 
properties. The effects of ellagic acid on cell cycle events and apoptosis
were studied in cervical carcinoma (CaSki) cells. We found that ellagic
acid at a concentration of 10(-5) M induced G arrest within 48 h, inhibited
overall cell growth and induced apoptosis in CaSki cells after 72 h of 
treatment. Activation of the cdk inhibitory protein p21 by ellagic acid 
suggests a role for ellagic acin in cell cycle regulation of cancer cells."



Focus: To Evaluate Red Raspberry Ellagic Acid in Prevention of Cervical Cancer

There is now clinical evidence to suggest that ellagic acid concentrations at 
tissue sites such as the cervix may be obtained with the oral administration 
of red raspberries. This belief comes from bioavailability studies in which 
human volunteers have ingested raspberry puree. Because of this and 
observations in human volunteers ingesting daily quantities of raspberry 
puree for prevention of colon cancer, a clinical trial will examine ellagic 
acid from raspberries in prevention of pre-cancerous cervical lesions 
developing into a malignant condition.

The proposed study, under the direction of Daniel Nixon, M.D., President of 
the American Health Foundation and Drs. Dave Gangemi and Blair Holliday of 
the Hollings Cancer Center/Medical University of South Carolina, will 
evaluate women with atypical squamous cells of undetermined significance 
(ASCUS) in which there is neither treatment nor clinical evaluation 
available. ASCUS represents as much as 10% of all Papanicolaou smears in the 
US and represents approximately 5 million females. In this population, these 
women who are infected with human papillomaviruses (HPV) types 16 and/or 18 
are at the greatest risk of developing cervical cancer at some stage in their 
lives. In addition, women who are diagnosed with the immature metaplastic 
form of ASCUS usually have lesions which are higher in the endocervical 
canal, are more metabolically active, have flatter surface areas, and are 
more likely to invade the underlying connective tissue as well as the 
endocervical glandular epithelium. This population represents approximately 
one million women in the United States alone. The condition is very 
pronounced in countries outside the United States. In India this is one of 
the two major cancers affecting women.

One way to evaluate the potential progression rate in these individuals is to 
monitor the levels of viral oncogene (E6/E7) messenger RNA expression in 
cervical tissue. The study with evaluate women with ASCUS who have little or 
no viral oncogene expression with those who have relatively elevated levels 
of HPV oncogene expression.

The Study Approach & Red Raspberry Dosage

The approach will orally administer ellagic acid (using red raspberry puree, 
the primary whole foods source of ellagic acid) at dosages providing 
detactable tissue levels in the cervix (Phase I of proposed study) over a 
two-year period (Phase II). Women in the study (to commence 1999-2000) will 
be carefully evaluated for any potential adverse effects of treatment and 
their E6/E7 levels carefully monitored every three months. Women receiving 
treatment will then undergo a full clinical evaluation at the end of the 
two-year trial period and changes in the levels of oncogene expression and in 
cervical pathology determined. Changes in women receiving the red raspberry 
dosage will be compared to changes in women receiving a placebo.

A biostatistician will evaluate the group sizes needed to determine a 
statistically significant change in ASCUS progression following ellagic acid 
(red raspberry) ingestion. Preliminary estimates indicate that five hundred 
women will be needed for the generation of valid predictions. Volunteers will 
be recruited from the MUSC Cancer Center Access Network, Clinics and the 
State Department of Health and Environmental Control. Entry will be based on 
pathological and cytological conditions discussed herein. Individuals will be 
divided into low and high HPV oncogene expression groups and each group 
further divided into ellagic acid and placebo groups.

Phase I Study

In Phase I, serum levels of ellagic acid will be monitored over a two-month 
period. At the end of this time cervical biopsies taken to determine tissue 
levels. Highly sensitive analytical techniques utilizing gas chromatographic 
mass spectroscopy will be utilized to measure tissue concentrations. The 
results from Phase I will be used to determine compliance rates and the daily 
dosage needed to detect ellagic acid in the cervix.

Phase II Study

In Phase II, cervical swabs will be taken from volunteers will well-defined 
cytopathological changes and the cells evaluated for HPV oncogene expression 
using a highly sensitive biomarkers assay (reverse transcriptase-polymerase 
chain reaction (RT-PCR). Individuals will receive oral dosages (to be 
determined from Phase I) of raspberry puree and be reevaluated every three 
months to determine the condition of their lesions (progressive, persistent, 
or regressive) using immunocytochemical techniques. Phase II will be a double 
blind placebo controlled study in which the research pharmacy laboratory will 
keep the treatment code. At the end of the two year period, date from each 
treatment group will be evaluated by a biostatistician and compared to 
placebo groups for changes in the rate of progression to Low Grade Cervical 
Intrepithelial Lesions (CINI). Any volunteer progressing to CINI during this 
study will be removed and given conventional therapy (colposcopy and biopsy, 
laser ablation, or loop excision of the transformation zone)

A barrage of clinical research at Hollings Cancer Center (Charleston, SC) 
confirms that red raspberries, the richest food source of a substance known 
as ellagic acid, inhibits the growth of cancer cells. Studies under the 
direction of Dr. Daniel Nixon indicate that daily consumption of 150grams (1 
cup) of red raspberries slows the growth of abnormal colon cells in humans, 
prevents (in some instances destroys) the development of cells infected with 
human papilloma virus (HPV) the cause of cervical cancer, and most recently 
found to break down extracted human leukemia cells.

Dr. Nixon's anti-cancer prowess comes at a time when most Americans seek to 
treat medical problems through changes in diet, rather than take medication. 
Foods containing significant levels of biologically active components that 
impart health benefits beyond basic nutrition when consumed in typical or 
optimal serving sizes, are fast-becoming the hot button for consumers. Red 
raspberries as the key source of cancer preventive, cancer fighting, and in 
some instances cancer cell destroying ellagic acid may be the ultimate 
cancer-fighting food today.

Food Sources of Ellagic Acid – micrograms/gm dry wt.

Red Raspberries1500
Strawberries630
Walnuts590
Pecans330
Cranberries120


Ellagic Acid is a naturally occurring phenolic constituent in certain fruits 
and nuts. Research in the past decade confirms that ellagic acid markedly 
inhibits the ability of other chemicals to cause mutations in bacteria. 
Ellagic acid from red raspberries has proven as an effective antimutagen and 
anticarcinogen as well as a inhibitor of cancer.